AbbVie Inc. (ABBV)
AbbVie Stock Is Rising on Strong Earnings. CEO Cites ‘Significant Momentum.
AbbVie reported second-quarter adjusted earnings of $2.65 a share on revenue of $14.46 billion.
Is AbbVie the Best Dividend Stock for You?
AbbVie lost its CEO last year even as its most important drug experienced a patent cliff. However, the company's business remains robust thanks to a deep lineup and rich pipeline.
AbbVie lifts annual profit forecast on strong immunology drug sales
AbbVie raised its annual profit forecast on Thursday as strong sales of its key immunology drugs, including Humira, helped it beat Wall Street expectations for the second quarter.
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
Arguably, there's never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, ABBV, VKTX, SNY and BMY, slated to release their second-quarter 2024 results this week.
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
AbbVie's lead drug, Humira, lost patent-protected market exclusivity in 2023, but sales have been relatively resilient to new competition. Despite losing billions in Humira revenue, total sales are still on the rise.
10 Best Dividend Growth Stocks to Buy and Hold Forever
These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
AbbVie (ABBV) closed at $172.32 in the latest trading session, marking a +0.69% move from the prior day.
AbbVie: Why I Sold My Shares At $175
We recently sold our ABBV shares at $175. The stock has reached our target valuation at this price. More fundamentally, we think the market has corrected its overreaction to the Humira patent cliff by now.
Earnings Preview: AbbVie (ABBV) Q2 Earnings Expected to Decline
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
AbbVie Inc. will announce its Q2 2024 earnings next Thursday, 25th July. The company has a new CEO, with insider Rob Michael taking the reins after long-term CEO Rick Gonzalez's retirement. Wall Street watches Humira's revenue post patent expiry in the US closely, and sold stock after Q1 showed a >30% YOY decline.
